Rigel Pharmaceuticals (RIGL) Revenue Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 122.97% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.94% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 4.47% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 54.05% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 31.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.16% |
| Dec 31, 2025 | 10.83% |
| Sep 30, 2025 | 45.80% |
| Jun 30, 2025 | 50.52% |
| Mar 31, 2025 | 47.16% |
| Dec 31, 2024 | 41.32% |
| Sep 30, 2024 | 36.93% |
| Jun 30, 2024 | 11.94% |
| Mar 31, 2024 | -28.56% |
| Dec 31, 2023 | 24.72% |
| Sep 30, 2023 | 15.23% |
| Jun 30, 2023 | 18.84% |
| Mar 31, 2023 | -22.39% |
| Dec 31, 2022 | 49.33% |
| Sep 30, 2022 | 2.42% |
| Jun 30, 2022 | 42.03% |
| Mar 31, 2022 | 9.85% |
| Dec 31, 2021 | -18.61% |
| Sep 30, 2021 | 64.21% |
| Jun 30, 2021 | 144.96% |
| Dec 31, 2020 | 82.86% |
| Sep 30, 2020 | 173.38% |
| Mar 31, 2020 | 149.64% |
| Dec 31, 2019 | 72.50% |
| Sep 30, 2019 | 77.02% |
| Jun 30, 2019 | 6.59% |
| Mar 31, 2019 | 35.91% |
| Dec 31, 2018 | 64.29% |
| Sep 30, 2018 | -27.93% |
| Jun 30, 2018 | -29.88% |
| Dec 31, 2016 | -19.50% |
| Jun 30, 2016 | 83.10% |
| Jun 30, 2015 | 51.19% |
| Mar 31, 2015 | 42.67% |
| Jun 30, 2013 | -69.52% |